Speakers - Sachs Associates

Speakers
Iain Buchanan, CEO, NOXXON Pharma AG
Iain was appointed CEO of NOXXON in September 2010 having worked closely with the board of directors since 2007 and
as a non-executive member of the supervisory board since 2009. He brings to the company over 30 years of commercial
experience in the pharmaceutical and biotech industries. Iain joined NOXXON from Novexel in Paris where he acted as
CEO since the Company’s formation in 2004 until its sale to AstraZeneca in 2009. Prior to Novexel, Iain held a variety of
management positions of increasing responsibility across various companies. These include Vertex Pharmaceuticals (Europe)
Limited where, as Managing Director, he was responsible for building a Vertex presence in Europe from 1994 to 2004, at Cilag
A.G. (a division of Johnson and Johnson based in Zug, Switzerland) where he managed the licensee business internationally
from 1987 to 1994 and at Biogen S.A. in Geneva, Switzerland from 1981 to 1987 where he oversaw commercial activities in
Europe. Iain began his career in Product Management at Merck Sharp & Dohme (UK) Limited in 1978.
Iain holds a Bachelor of Science in Physiology from the University of St Andrews, Scotland and is a non-Executive Director of
Synairgen plc based in Southampton UK.
Ilka Wicke, Director, Boehringer Ingelheim Venture Fund
Ilka joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery
approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over the last 10 years
gained extensive experience in the evaluation, negotiation and the management of global licensing transactions.
Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for oncology, urology and
metabolism where she was responsible for the identification and evaluation of pre-clinical and clinical licensing opportunities
as well as structuring and negotiating technology and licensing agreements. She later joined the transaction group of
Corporate Licensing where she was responsible for the negotiation and conclusion of a variety of global licensing agreements.
Ilka has a PhD in organic chemistry from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she
spent a year as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy
approaches to stimulate antitumour responses.
Jacques Nasstrom, CEO, PledPharma AB
Jacques has a basic training as Pharmacist with PhD in Pharmacology from Uppsala University, Sweden and a Business
degree from Stockholm School of Economics. He has 25 years of experience from the pharmaceutical and biotechnology
industries, including a position as Investment Manager at Karolinska Investment Fund, Stockholm Sweden, and various
management positions within drug discovery at Astra and AstraZeneca, Södertälje, Sweden and most recently as Director
of Research & Development at Q-Med AB, Uppsala, Sweden from 2006-2010. Since 2010, Jacques is CEO of PledPharma
which is a Swedish based specialty pharma company that develops a new medicine, PledOx®, for prevention of the severe
side effects that patients develop as a consequence of chemotherapy treatment of cancer.
Jakob Knudsen, CEO, ViroGates A/S
Jakob assumed his role as CEO of ViroGates in April 2011. Jakob was previously CCO & CFO of Egalet Ltd. a Danish based biotech
company focusing on development of pain products. Jakob oversaw all commercial operations including IP and Financing, and
was responsible for entering into multiple commercial collaborations (licensing and feasibility stage agreements). Prior to this
Jakob was heading the Corporate Business Development function at ALK-Abelló A/S, a Danish biopharmaceutical company.
Jakob was responsible for ALK’s licensing and M&A deals. Before this Jakob held positions within sales and marketing with
the company. Jakob is a lawyer by training and he also holds an MBA from Imperial College, UK.
Jan K Öhrström, CEO, ProFibrix BV
Jan is CEO and President of ProFibrix BV. Dr Öhrström has 20+ years biotech industry experience from companies in EU and
the US. He started his career at Novo Nordisk A/S in 1990 and held various positions of increasing seniority within Development
and Business/Marketing in Denmark and the US. Dr Öhrström joined the Senior Management Team at ZymoGenetics Inc in
Seattle in 2000, and was part of the Management Team that took the company public (Nasdaq:ZGEN) in 2002. Dr Öhrström
was responsible for establishing the company’s development and business infrastructure. During his tenure at ZymoGenetics
Inc, the company submitted its first BLA (RecoThrom©) that was approved in 2008. Dr Öhrström joined ProFibrix in 2008,
incorporated the company in the US, and in 2011 he was promoted to CEO. He is an MD from University of Copenhagen and
completed 6 years of clinical practice prior to joining the pharmaceutical industry.
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS